Diabetes mellitus type 2 is associated with greater bone mineral density (BMD) due to obesity, although rapid bone loss observed over time could be explained by elevated chronic inflammation. The objective of this study was to investigate the relationship between central adiposity and hyperinsulinemia, as well as inflammation markers with vertebral and femoral BMD and bone turnover markers in postmenopausal women with type 2 diabetes. Femoral and vertebral BMD, osteocalcin, pyrilinks D, beta-CrossLaps (B-CTx), insulin, C-reactive protein (CRP), fibrinogen and plasminogen activator inhibitor-1 (PAI-1) were measured in 114 postmenopausal female patients with diabetes type 2. The patients of similar age, HbA1c levels and diabetes duration were divided into 2 groups based on their body mass index (BMI) values: lower or equal to 27 kg/m 2 (31 patients) and higher than 27 kg/m 2 (83 patients). Lower levels of osteocalcin (p=0.001), B-CTx (p=0.000007) and pyrilinks D (p=0.0365), and higher femoral BMD (p=0.00006), insulin level (p=0.0002), PAI-1 (p=0.00000) and CRP (p=0.002) were found in the overweight group. There were no significant differences in vertebral BMD and fibrinogen. Osteocalcin and B-CTx showed inverse correlation, and femoral BMD positive correlation with waist circumference, insulin level and PAI-1. This suggests that abdominal obesity and hyperinsulinemia as components of the metabolic syndrome could increase femoral BMD by lowering bone rate. In addition, the only inflammation marker linked with femoral BMD was PAI-1, which is associated with increased mineralization of cortical bone in mouse models.
Introduction
Diabetes mellitus type 2 (T2DM) can influence bone through several mechanisms, some of which may have contradictory effects. Obesity or high body mass index (BMI) has a protective effect against excessive bone loss with aging [1] [2] [3] [4] . This is probably a result of enhanced osteoblast differentiation due to heavier mechanical loading of bone, whereas hyperinsulinemia may promote bone formation 5 . Higher glucose levels in the blood interact with several proteins generating higher concentration of advanced glycation end-products (AGEs) in collagen that may reduce bone strength 6 . Accumulated AGEs in the body may stimulate apoptosis of osteoblasts, thereby contributing to deficient bone formation 7 .
The metabolic syndrome includes obesity, dyslipidemia, impaired glucose tolerance, and hypertension 8 , and is also associated with low-grade inflammation, as well as diabetes mellitus type 2 (T2DM) 9 . In osteoporosis, bone mineral density (BMD) is reduced and bone microarchitecture deteriorated, which leads to an increased risk of fracture 10 . Proinflammatory cytokines up-regulate receptor activator of nuclear factor-κB ligand, leading to increased bone resorption [11] [12] [13] . Some authors have suggested that elevated C-reactive protein (CRP) is associated with osteoporosis and nontraumatic fracture 14, 15 .
Many studies investigated the relationship between T2DM and bone metabolism, but their results were inconsistent. For patients with T2DM, some authors have reported increased BMD, others have reported decreased BMD, and some have reported unaltered BMD 16 .
The aim of this study was to investigate the relationship between components of the metabolic syndrome, central adiposity and hyperinsulinemia, as well as inflammation markers with vertebral and femoral BMD and bone turnover markers in postmenopausal women with T2DM.
Materials and Methods

Subjects
This study complied with the Declaration of Helsinki and was approved by the Ethics Committee of the Osijek University Hospital Center. The subjects enrolled in the study were a subset of all patients having visited or being hospitalized for regular medical check-up at the Department of Endocrinology and Diabetes, Osijek University Hospital Center. This cross-sectional study included 114 female postmenopausal patients with T2DM aged ≥45 years, with similar HbA1c levels and diabetes duration, divided into 2 groups based on their BMI values: lower or equal to 27 kg/m 2 (31 patients) and higher than 27 kg/m 2 (83 patients) 17 . Patients with a history of the following conditions were excluded from the study: those taking medication for osteoporosis; those receiving hormone replacement therapy or other medications such as glu-cocorticoids, affecting BMD; those with conditions such as malignancy, thyroid disease or thyroid functional abnormality that would be apparent causes for abnormal bone mass; and those with acute infectious disease or chronic inflammatory diseases. BMI was calculated from body weight and height (kg/m 2 ). Waist circumference at the bending point was measured in centimeters with the participant wearing only a single layer of clothes. Postmenopausal status was defined, through close history taking, as cessation of menstruation for at least 1 year.
BMD measurement
Bone mineral density of lumbar spine and total femur was measured by dual energy x-ray absorptiometry (Dexa QDR 1000, Hologic, Inc., Waltham, MA, USA) calibrated daily using a standard phantom provided by the manufacturer. Lumbar spine BMD was the mean of lumbar vertebrae 1-4.
Biochemical assay
At study entry, all women underwent blood analyses to verify their healthy state. Bone metabolism was evaluated by determining serum levels of osteocalcin (OC) as a marker of bone formation, and urinary pyrilinks-D (PYD) and beta-CrossLaps (B-CTx) as markers of bone resorption 18 . Second morning urine sample was collected and PYD in urine was measured using competitive enzyme immunoanalysis by commercially available kit, according to the manufacturer's protocol (Metra Biosystem Inc., Mountain View, USA; reference value 3.0-7.4 nM DPD/mM creatinine). Serum OC levels were assayed by an immunoradiometric assay (IRMA) with commercially available kits, according to the manufacturer's recommendations (Bio-Source Europe S.A., Nivelles, Belgium; reference value 5-25 ng/mL). Serum Beta-CTx was measured by electrochemiluminescent immunoassay (ECLIA) by commercially available kit, according to the manufacturer's protocol (Roche-B-Crosslaps assay, Roche Diagnostics, Mannheim, Germany). Serum insulin levels were determined with RIA method. Automated CRP measurement was performed by immunoturbidimetry on a modular clinical analyzer (Olympus, Beckman Coulter, Inc., USA). Fibrinogen and plasminogen activator inhibitor-1 (PAI-1) were determined by coagulometry Ines Bilić-Ćurčić et al.
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Statistical analysis
Results were processed using descriptive statistical analysis. Continuous variables were summarized using sample size, mean, median, standard deviation, and minimum and maximum values. Significance was declared at a two-sided 0.05 level, unless otherwise specified. Mann Whitney as a non-parametric test was used to calculate distribution differences for continuous variables. Spearman's correlation coefficients were computed to estimate the magnitude of the association between the variables of interest. Statistical analysis was performed using StatSoft, Statistica 8.0.
Results
Baseline characteristics of the subjects are summarized in Table 1 . Both groups had similar diabetes duration and HbA1c levels. There was no significant difference in vertebral BMD or fibrinogen between the two groups. The mean values of PAI-1 (p=0.000000), CRP (p=0.002) and insulin (p=0.0002), as well as total femoral BMD (p=0.00006) were significantly higher, whereas bone turnover markers, i.e. osteocalcin (p= 0.001), B-CTx (p=0.000007) and pyrilinks D (p= 0.0365) were significantly lower in the overweight group. This could suggest that bone activity was sup- Table 2 pressed as a result of hyperinsulinemia present in patients with visceral obesity, thus blocking bone resorption leading to higher femoral BMD. Spearman's correlation yielded a strongly significant negative association of B-CTx and OC with waist circumference, insulin levels and PAI-1 (Table  2) , also indicating supression of bone turnover rate due to hyperinsulinemia. Furthermore, there was no corellation between inflammation markers (CRP and fibrinogen) and bone turnover markers. Total femoral BMD was significantly positively associated with waist circumference, insulin levels and PAI-1, while vertebral BMD correlated significantly only with waist circumference ( Table 2 ). There was no correlation with CRP or fibrinogen.
. Correlation of bone mineral density and bone turnover markers with inflammatory markers and components of metabolic syndrome
Discussion
Although it is generally accepted that obesity has a protective effect on bone tissue, some studies have revealed the opposite, i.e. that obesity is not beneficial or has a negative effect on osteoporosis. In a study of postmenopausal Korean women 19 , waist circumference, which provides an indication of central obesity (visceral fat mass), was related to low BMD and osteoporotic vertebral fractures. In contrast, our research demonstrated significant positive correlation between vertebral and femoral BMD and waist circumference, which could be explained by higher circulating insulin levels in central obesity. Consequently, hyperinsulinemia significantly correlated with higher femoral BMD, but was negatively associated with bone turnover markers, suggesting inhibition of bone resorption due to suppression of bone activity.
Diabetes mellitus type 2 is a condition that includes obesity, a factor associated with enhanced BMD, and inflammation, a factor thought to reduce BMD, which could be present in all types of diabetes 20,21 . However, low grade inflammation is more severe in subjects with high insulin resistance than in those with low insulin resistance 22, 23 , presumably leading to reduced BMD in T2DM. Some studies have suggested that chronic inflammation has a deleterious effect on BMD, resulting in development of osteoporosis 14, 24 . Therefore, T2DM has a potential dual effect on bone health, i.e. protective effect due to obesity and adverse one as a result of bone resorption activated by chronic inflammation.
Whereas previous work suggests that osteoporosis is linked to inflammation, it is not yet clear whether higher CRP levels are associated with bone loss 15 . In a recently published study, CRP was associated inversely with composite strength index, but was not associated with femoral neck or lumbar spine BMD 25 , which is consistent with our observation. The only inflammation marker linked with higher femoral BMD was PAI-1, a recognized modulator of matrix implicated in the regulation of bone homeostasis. Over-expression of PAI-1 in transgenic mice resulted in increased mineralization and biomechanical properties of mouse femora 26 . In a study performed on PAI-1 knockout mice, PAI-1 (and potentially the plasminogen extracellular matrix protease system) was demonstrated to be an important regulator of bone size during developmental growth, playing a regulatory role in the determination of fracture callus size, cartilage formation, and resorption during bone fracture repair 27 . PAI-1 also negatively correlated with bone turnover markers, once again suggesting higher mineral density as a result of inhibited bone resorption. In a recently published study increased PAI levels were associated with higher BMD in obese diabetic female patients implicating direct involvement in bone metabolism 28 .
Total femoral BMD was significantly higher in the overweight group, whereas no significant difference in the vertebral BMD was noted, implying that the effects of obesity and hyperinsulinemia on BMD varied by anatomic site, as shown in previous studies 29 .
Our study had some limitations. Since our data were cross-sectional, we had a limited ability to assess temporal relationship between the components of metabolic syndrome and BMD. Further longitudinal studies are needed to elucidate the association between bone and energy metabolism.
These findings suggest that the protective effect of the metabolic syndrome components, i.e. abdominal obesity and hyperinsulinemia in T2DM could prevail over deleterious effect of chronic inflammation on bone metabolism, thus resulting in increased total femoral BMD.
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